Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
Head and Neck Neoplasms
Interventions
BIOLOGICAL

Monalizumab

BIOLOGICAL

Cetuximab

BIOLOGICAL

Anti-PD(L)1

Trial Locations (18)

10029

Icahn School of Medicine at Mount Sinaï, New York

19104

University of Pennsylvania, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

60637

University of Chicago, Chicago

94305

Stanford Cancer Center, Stanford

Unknown

University of California, Moores Cancer Center, La Jolla

University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore

Washington University School of Medicine, St Louis

Vanderbilt University Medical Center, Nashville

Centre Jean Perrin, Clermont-Ferrand

Centre Oscar Lambret, Lille

Centre Leon Berard, Lyon

Hopital La Timone, Marseille

Institut Regional du Cancer de Montpellier, Montpellier

Centre Antoine Lacassagne, Nice

Centre Eugene Marquis, Rennes

ICO Rene Gauducheau, Saint-Herblain

Institut Gustave Roussy, Villejuif

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Innate Pharma

INDUSTRY